Overview

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

Status:
RECRUITING
Trial end date:
2026-02-28
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Phase:
PHASE2
Details
Lead Sponsor:
Suven Life Sciences Limited